Paper Details

  1. Home
  2. Paper Details

Dacomitinib: First Global Approval.

Author: ShirleyMatt

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dacomitinib, a small-molecule inhibitor of HER1 (EGFR), HER2, and HER4, received its first global approval for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations.
Paper Details　
Original Abstract of the Article :
Dacomitinib (Vizimpro<sup>&#174;</sup>) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours. In September 2018, dacomitinib received its first global approval, in the USA, for use in the f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40265-018-1028-x

データ提供：米国国立医学図書館（NLM）

A New Weapon in the Arsenal: Dacomitinib Approved for First-Line Treatment of EGFR-Mutated NSCLC

Non-small cell lung cancer (NSCLC), a formidable foe in the fight against cancer, has been the subject of intensive research. This article highlights the [first global approval of dacomitinib, an irreversible inhibitor of HER1, HER2, and HER4, for the first-line treatment of patients with EGFR-mutation-positive metastatic NSCLC]. The approval is based on clinical trials demonstrating the effectiveness of dacomitinib in extending survival and improving quality of life for patients with this specific type of lung cancer.

A Targeted Approach: Dacomitinib Offers Hope for EGFR-Mutated NSCLC Patients

The approval of dacomitinib marks a significant advancement in the [treatment of EGFR-mutation-positive metastatic NSCLC]. By targeting specific mutations in the EGFR pathway, dacomitinib offers a personalized approach to treating lung cancer, potentially leading to improved outcomes for patients.

Navigating the Cancer Landscape: Understanding Personalized Treatment Options

This article underscores the importance of [personalized medicine] in cancer treatment. With advancements in molecular diagnostics and targeted therapies, healthcare providers can now tailor treatment plans based on the specific genetic characteristics of a patient's cancer. This approach allows for more effective and less toxic treatments, potentially improving patient outcomes and quality of life.

Dr. Camel's Conclusion

The battle against cancer is a long and arduous journey. This article offers a beacon of hope for patients with EGFR-mutation-positive metastatic NSCLC, highlighting the potential of dacomitinib to improve outcomes. By embracing personalized medicine and harnessing the power of targeted therapies, we can navigate the complex landscape of cancer treatment with greater precision and hope.
Date :
  1. Date Completed 2019-07-18
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

30506139

DOI: Digital Object Identifier

10.1007/s40265-018-1028-x

Related Literature

Article Analysis
・Effects of dacomitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.